Clinical Trial Update: A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the combination of THR-317 and Ranibizumab for diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus
• Diabetic Macular Edema
• Diabetic Retinopathy

Drugs mentioned

• Ranibizumab (ranibizumab)
• THR-317

Snippet

Sponsor: Oxurion | Conditions: Diabetes Mellitus, Diabetic Retinopathy | Phase 2 | Status: COMPLETED